Casdin Partners Master Fund, L.P.'s Net Worth
Estimate Recalculated Oct 6, 2025 08:24PM EST
Who is Casdin Partners Master Fund, L.P.
Casdin Partners Master Fund, L.P. has an estimated net worth of $167 Million. This is based on reported shares across multiple companies, which include STANDARD BIOTOOLS INC., CONSTELLATION PHARMACEUTICALS INC, Fulcrum Therapeutics, Inc., Absci Corp, BIOLIFE SOLUTIONS INC, MAXCYTE, INC., GeneDx Holdings Corp., 2seventy bio, Inc., Tenaya Therapeutics, Inc., Verve Therapeutics, Inc., and Decibel Therapeutics, Inc..
SEC CIK
Casdin Partners Master Fund, L.P.'s CIK is 0001534265
Past Insider Trading and Trends
2021 was Casdin Partners Master Fund, L.P.'s most active year for acquiring shares with 9 total transactions. Casdin Partners Master Fund, L.P.'s most active month to acquire stocks was the month of June. 2021 was Casdin Partners Master Fund, L.P.'s most active year for disposing of shares, totalling 4 transactions. Casdin Partners Master Fund, L.P.'s most active month to dispose stocks was the month of June. 2020 saw Casdin Partners Master Fund, L.P. paying a total of $75,363,460.00 for 4,971,536 shares, this is the most they've acquired in one year. In 2022 Casdin Partners Master Fund, L.P. cashed out on 3,971,334 shares for a total of $18,437,940.30, their largest year based on trade value.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
